A Phase I Dose-Escalation and Expansion Study of RMX1002, a Selective E-type Prostanoid Receptor 4 Antagonist, As Monotherapy and in Combination with Anti-Pd-1 Antibody in Advanced Solid Tumors
Investigational New Drugs（2025）
Key words
RMX1002,Grapiprant,Prostaglandin E2,EP4,Immunotherapy,Solid tumors
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined